Remove Branding Remove Clinical Supply Remove Contract Manufacturing Remove Licensing
article thumbnail

Abiogen acquires EffRx to fortify bone disease portfolio

Pharmaceutical Technology

The company’s last deal included an exclusive license agreement with the Cardiff, UK-headquartered specialty pharmaceuticals company Diurnal group for the commercialisation of Efmody (hydrocortisone) in Switzerland. The biotech transferred the rights for alendronate to Merck which marketed the drug under the brand name Vancapsi.